BIOMARKER OF CHRONIC KIDNEY DISEASE IN LIVER TRANSPLANT RECIPIENTS

摘要

Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from the subject prior to the subject being administered a liver transplant procedure and/or after the subject has been administered the liver transplant procedure. Suitable protein markers for the disclosed methods may include but are not limited to osteopontin (OPN) and/or tissue inhibitor of metalloproteases 1 (TIMP1).